LA
REGN icon

Lifeworks Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Lifeworks Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-562
Closed -$434K – 330
2025
Q4 		$434K Sell
562
-1,276
-69% -$867K 0.06% 225
2025
Q3 		$1.03M Sell
1,838
-59
-3% -$33.4K 0.14% 135
2025
Q2 		$996K Sell
1,897
-7,012
-79% -$3.91M 0.15% 129
2025
Q1 		$5.65M Buy
8,909
+2,166
+32% +$1.49M 0.94% 29
2024
Q4 		$4.8M Buy
6,743
+1,617
+32% +$1.36M 0.87% 32
2024
Q3 		$5.39M Sell
5,126
-203
-4% -$226K 1.06% 27
2024
Q2 		$5.6M Buy
5,329
+425
+9% +$412K 1.56% 18
2024
Q1 		$4.72M Buy
4,904
+590
+14% +$561K 1.32% 21
2023
Q4 		$3.79M Sell
4,314
-202
-4% -$166K 1.31% 20
2023
Q3 		$3.72M Buy
4,516
+243
+6% +$191K 1.45% 20
2023
Q2 		$3.07M Buy
4,273
+767
+22% +$591K 1.31% 23
2023
Q1 		$2.88M Sell
3,506
-189
-5% -$143K 1.36% 21
2022
Q4 		$2.67M Buy
3,695
+191
+5% +$141K 1.5% 21
2022
Q3 		$2.62M Sell
3,504
-283
-7% -$178K 1.49% 20
2022
Q2 		$2.24M Buy
+3,787
New +$2.46M 1.42% 20

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Lifeworks Advisors's REGN Position: Q1 2026 in Review

Lifeworks Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 562 shares — an estimated $434K sold.

Lifeworks Advisors first reported a position in REGN in Q2 2022 and held it in 15 quarters. The position peaked at $5.65M in Q1 2025. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Lifeworks Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Lifeworks Advisors sold 562 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $434K.
  • Lifeworks Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2022 and held it in 15 quarters.
  • Lifeworks Advisors's Regeneron Pharmaceuticals position peaked at $5.65M in Q1 2025.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Lifeworks Advisors's 13F filing for Q1 2026, filed 4 May 2026.